Drug treatment and the conditionality of HIV treatment access: A qualitative study in a Russian city

Addiction

Volumn 107, Issue 10, 2012, Pages 1827-1836

  Rhodes, Tim ^a,b   Sarang, Anya ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Andrey Rylkov Foundation for Health and Social Justice   (Russian Federation)

Author keywords

Antiretroviral HIV treatment (ART); HIV; Injecting drug use; Opioid substitution treatment (OST); Russia

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CITY; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; OPIATE ADDICTION; PATIENT ATTITUDE; PSYCHOLOGICAL ASPECT; RUSSIAN FEDERATION; STATISTICS; SUBSTANCE ABUSE;

ADULT; ANTI-HIV AGENTS; CITIES; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MIDDLE AGED; OPIOID-RELATED DISORDERS; PATIENT ACCEPTANCE OF HEALTH CARE; RUSSIA; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84866044851     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2012.03880.x     Document Type: Article

References (54)

1. Werb D., Mills E. J., Montaner J. S. G., Wood E. Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis. Lancet Infect Dis 2010; 10: 464-9.
2. Muga R., Langohr K., Tor J., Sanvisens A., Sera I., Celestino R.-J. etal. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex-and age-specific survival of HIV-unifected IDUs. Clin Infect Dis 2007; 45: 370-6.
3. Ferreros I., Lumbreras B., Hurtado I., Perez-Hoyos S., Hernandez-Aguado I. The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users. Addiction 2008; 103: 651-9.
4. Wood E., Kerr T., Marshall B. D. L., Li K., Zhang R., Hogg R. S. etal. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 2009; 338: b1649.
5. Lundgren J. D., Babiker A., El-Sadr W., Emery S., Grund B., Neaton J. D. etal. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ cell counts and HIV-RNA levels during follow-up. J Infect Dis 2008; 197: 1145-55.
6. Carrieri M. P., Spire B. Forced treatment interruptions and risk of HIV resistance in countries adopting law enforcement against marginalized populations. AIDS 2007; 21: 1062-3.
7. Deeks S. G. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003; 362: 2002-11.
8. Carrieri M. P., Moatti J. P., Vlahov D., Obadia Y., Reynaud-Maurupt C., Chesney M. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of controlled drug use. J Epidemiol Commun Health 1999; 53: 4-8.
9. Lai T., Ratsep M., Ruutel K., Tummel A., Kahur K., Nielsen S. etal. Modelling Estonia's Concentrated HIV Epidemic. Tallinn: World Health Organization Regional Office for Europe and Estonian National Institute for Health Development; 2009.
10. Spire B., Lucas G. M., Carrieri P., Gallais H., Moreau J., Moatti J. P. etal. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment. Int J Drug Policy 2007; 18: 262-70.
11. Lucus G. M., Cheever L. W., Chaisson R. E., Moore R. D. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001; 27: 251-9.
12. Krusi A., Wood E., Montaner J., Kerr T. Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy 2010; 21: 4-9.
13. Wolfe D., Carrieri M. P., Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 2010; 376: 355-66.
14. Bouhnik A. D., Chesney M., Carrieri P., Gallais H., Moreau J., Moatti J. P. etal. Nonadherence among HIV-infected injecting drug users: the impact of social instability. J Acquir Immune Defic Syndr 2002; 31: S149-S153.
15. Leaver C. A., Bargh G., Dunn J. R., Hwang S. W. The effects of housing status on health-related outcomes in people living with HIV: a systematic review of the literature. AIDS Behav 2007; 11: 85-100.
16. Lambers F., Stolte I. G., Van Den Berg C., Coutinho R., Prins M. Harm reduction intensity: its role in HAART adherence amongst drug users in Amsterdam. Int J Drug Policy 2011; 22: 210-8.
17. Milloy M. J., Kerr T., Buxton J., Rhodes T. etal. Dose-response effect of incarceration events on non-adherence to HIV antiretroviral therapy among injection drug users. J Infect Dis 2011; 203: 1215-21.
18. Kavasery R., Galai N., Astemborski J. etal. Nonstructured treatment interruptions among injection drug users. AIDS Care 2005; 17: 539-49.
19. Ding L., Landon B. E., Wilson I. B., Wong M. D., Shapiro M. F., Cleary P. D. Predictors and consequences of negative physician attitudes towards HIV-infected drug users. Arch Intern Med 2005; 165: 618-23.
20. Loughlin A., Metsch I., Gardner L., Anderson-Mahoney P., Barrigan M., Strathdee S. Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users. AIDS Care 2004; 16: 485-500.
21. Degenhardt L., Mathers B., Vickerman P., Rhodes T., Latkin C., Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural and combination approaches are needed. Lancet 2010; 376: 285-301.
22. Rhodes T., Sarang A., Vickerman P., Hickman M. Policy resistance to harm reduction for drug users and potential effect of change. BMJ 2010; 341: c3439.
23. Uhlmann S., Milloy M. J., Kerr T., Zhang R., Guillemi S., Marsh D. etal. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction 2010; 105: 907-13.
24. Wood E., Hogg R. S., Kerr T., Palepu A., Zhang R., Montaner J. S. Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naïve HIV-infected injection drug users. AIDS 2005; 19: 837-39.
25. Weber R., Huber M., Rickenbahc M., Furrer H., Elzi L., Hirschel B. etal. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV cohort study. HIV Med 2009; 10: 407-16.
26. Pelapu A., Tyndall M. W., Joy R., Kerr T., Wood E., Press N. etal. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected drug users: the role of methadone maintenance therapy. Drug Alcohol Depend 2006; 84: 188-94.
27. Roux P., Carrieri M. P., Villes V., Dellamonica P., Poizot-Martin I., Ravaux I. etal. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction 2008; 103: 1828-36.
28. Lucas G. M., Mullen B. A., Weidle P. J., Hader S., McCaul M. E., Moore R. D. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis 2006; 42: 1628-235.
29. Roux P., Carrieri M. P., Cohen J. etal. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis 2009; 49: 1433-40.
30. Lloyd-Smith E., Brodkin E., Wood E., Kerr T., Tyndall M. W., Montaner J. S. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS 2006; 20: 445-50.
31. Tyndall M. W., McNally M., Lai C., Zhang R., Wood E., Kerr T. etal. Directly observed therapy programmes for antiretroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes. Int J Drug Policy 2007; 18: 281-7.
32. Altice F. L., Maru D. S., Bruce R. D., Springer S. A., Friedland G. H. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis 2007; 45: 770-8.
33. Mathers B. M., Degenhardt L. J., Phillips B., Wiessing L., Hickman M., Strathdee S. etal. Global epidemiology of injecting drug use and HIV among people who inject drugs. Lancet 2008; 372: 1733-45.
34. United Nations General Assembly Sixtieth Special Session. Political Declaration on HIV/AIDS. Resolution 60/262 adopted by the United Nations General Assembly. New York: United Nations; 2006.
35. Mathers B., Degenhardt L., Ali H., Wiessing L., Hickman M., Mattick R. P. etal. HIV prevention, treatment and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375: 1014-28.
36. Mattick R. P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; 1: CD006140.
37. Palmateer N., Kimber J., Hickman M., Hutchinson S., Rhodes T., Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction 2010; 105: 844-59.
38. Babyan E., Gnonopolsky M. Alcoholism and Drug Abuse in the Soviet Union. New York: International Universities Press; 1985.
39. Layder D. New Strategies in Social Research. London: Wiley; 1993.
40. Sverdlovsk Oblast AIDS Centre. Data on the HIV situation in Sverdlovsk Oblast as of December 2010. Available at: http://www, livehiv.ru/index.php?page-epi&pid=1612 (accessed 28 November 2011; archived by Webcite at http://www.webcitation.org/6718psgOx).
41. Evans K. Concepts of bounded agency in education, work, and the personal lives of young adults. Int J Psychol 2007; 42: 85-93.
42. Giddens A. The Constitution of Society. Cambridge: Polity; 1984.
43. Hammer S. M., Eron J. J., Reiss P., Schooley R. T., Thompson M. A., Walmsley S. etal. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society. JAMA 2008; 300: 555-70.
44. World Health Organization (WHO). HIV/AIDS Treatment and Care: Clinical Protocol for the WHO European Region. Copenhagen: World Health Organization; 2006.
45. Goffman E. Stigma. Harmondsworth: Penguin; 1963.
46. Robins R. From 'rights' to 'ritual': AIDS activism in South Africa. Am Anthropol 2006; 108: 312-23.
47. Nguyen V. K., Ako C. Y., Niamba P., Sylla A., Tiendrebeogo I. Adherence as therapeutic citizenship: impact of the history of access to antiretroviral drugs on adherence to treatment. AIDS 2007; 5 (suppl): S31-S35.
48. Biehl J. Will to Live: AIDS Therapies and the Politics of Survival. Oxford: Princeton University Press; 2007.
49. Wolfe D. Paradoxes in antiretroviral treatment for injecting drug users: access, adherence and structural barriers in Asia and the former Soviet Union. Int J Drug Policy 2007; 18: 246-54.
50. Donoghoe M. C., Bollerup A. R., Lazarus J. V., Nielsen S., Matic S. Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European region. Int J Drug Policy 2007; 18: 271-80.
51. Maron E. Assessment of HIV Treatment Barriers in 20 Russian Cities. St Petersburg, Russia: SIMONA+; 2010.
52. Bobrova N., Rhodes T., Power R. etal. Barriers to accessing drug treatment in Russia: a qualitative study among injecting drug users in two cities. Drug Alcohol Depend 2006; 82: S57-S63.
53. Elovich R., Drucker E. On drug treatment and social control: Russian narcology's great leap backwards. Harm Reduct J 2008; 5: 23. doi:10.1186/1477-7517-5-23.
54. Human Rights Watch. Rehabilitation Required: Russia's Human Rights Obligation to Provide Evidence-Based Drug Dependence Treatment. New York: Human Rights Watch; 2007.